Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors

Prior treatment

• Failure to recover from toxic effects or complications of prior interventions (≤ grade 1 or baseline levels, excluding fatigue or hair loss).
• Any arterial thrombotic or embolic events within 6 months before enrollment (e.g., myocardial infarction, cerebrovascular accident, transient ischemic attack).
• Women of childbearing potential without a negative pregnancy test prior to study entry.

Other illness

• Severe or uncontrolled systemic diseases, including:
• Major, symptomatic arrhythmias or significant ECG abnormalities (e.g., complete left bundle branch block, second-degree or higher heart block, or ventricular arrhythmias).
• Unstable angina or congestive heart failure (NYHA class ≥ 2).
• Active or uncontrolled infections requiring systemic treatment.
• Severe psychiatric disorders affecting study participation.
• Known allergy or hypersensitivity to \[18F\]AlF-NOTA-PCP2 or any component of the radiopharmaceutical.

Lab values

• Any medical history, laboratory abnormality, or condition that may:

Other

• Participation in another interventional clinical trial.
• Pregnant or breastfeeding women.
• Interfere with study results.
• Affect patient participation.
• Pose an unacceptable risk as determined by the investigator.

• Signed informed consent obtained.
• Age ≥ 18 years, any gender.
• Pathologically confirmed malignant tumors, including:
• Glioblastoma
• Head and neck squamous cell carcinoma
• Non-small cell lung cancer
• Esophageal cancer
• Detectable PD-L1 expression in tumor tissue (based on immunohistochemistry or biopsy).
• Measurable disease with at least one residual tumor lesion.
• ECOG performance status of 0-1.
• No contraindications to \[18F\]AlF-NOTA-PCP2 PET/CT imaging.
• Willing and able to comply with study procedures and follow-up visits.